Awaiting development: Guidance and quality standards

Showing 141 to 150 of 335

Guidance and quality standards awaiting development
Title	Type
Isatuximab in combination as induction therapy for untreated multiple myeloma when an autologous stem cell transplant is suitable TS ID 11949	Technology appraisal guidance
Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease [ID3868]	Technology appraisal guidance
Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]	Technology appraisal guidance
Larotrectinib for treating NTRK fusion-positive solid tumours (MA review of TA630) [ID6292]	Technology appraisal guidance
Lazertinib with amivantamab and platinum-based chemotherapy for EGFR mutation-positive metastatic non-small-cell lung cancer after a tyrosine kinase inhibitor TS ID 11822	Technology appraisal guidance
Leadless cardiac pacemaker implantation for bradyarrhythmias	Interventional procedures guidance
Lenacapavir for HIV pre-exposure prophylaxis in people 16 years and over at risk of infection [ID6495]	Technology appraisal guidance
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]	Technology appraisal guidance
Leriglitazone for treating X-linked andrenoleukodystrophy TS ID 9996	Technology appraisal guidance
Letermovir for preventing cytomegalovirus infection in people under 18 years after allogeneic haematopoietic stem cell transplant TS ID 11868	Technology appraisal guidance